Table 4c Mean (s.d.) pharmacokinetic parameters of tipifarnib (200 mg) as monotherapy, or with gemcitabine (750–1000 mg m−2) and cisplatin (75–100 mg m−2)

From: Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours

Variable

Units

Tipifarnib (s.d.) n =20

Tipifarnib+gem/cis (s.d.) n =23

P -value a

Tipifarnib

 Median tmax

Hours

3.0

2.1

—

 Cmax

ng ml−1

499 (275)

635 (366)

0.094b

 AUC0-12

h ng ml−1

2630 (1134)

2971 (2089)c

0.918b

  1. aTwo-sided P-value in log-scale for testing a difference between the two treatments. Only data from patients who completed the study were included.
  2. bn=20.
  3. cn=22.
  4. Gem=gemcitabine; cis=cisplatin.
Back to article page